POST ALLOGENIC TRANSPLANT RELAPSE OF HODGKIN LYMPHOMA SALVAGED WITH CHEMOTHERAPY AND DONOR LEUCOCYTE INFUSION

The use of non myeloablative and reduced intensity conditioning regimens have greatly reduced the treatment related mortality (TRM) associated with allografting for Hodgkin lymphoma (HL) and disease relapse is now the most common cause of treatment failure. The two major treatment strategies for relapsed HL after allogenic stem cell transplant (SCT) have been salvage chemo radiotherapy and donor leucocyte infusion (DLI). Evidence supporting a potent allogenic graft versus Hodgkin lymphoma (GVHL) effect is increasingly compelling and DLIs have gained a prominent role in the management of HL patients who relapse following allogenic SCT. We report a case of relapsed HL after allogenic SCT salvaged by chemotherapy and adaptive immunotherapy